傍神経節腫の世界市場レポート 2025年

傍神経節腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR4.7％で36億4,000万米ドルに成長します。予測期間の成長は、新たな標的療法や免疫療法、放射性医薬品の拡大、遺伝性疾患の有病率の上昇、希少疾患研究への投資の増加、新興市場におけるヘルスケアアクセスの改善などに起因すると考えられます。この期間に予想される主要動向には、標的療法の進展、放射性医薬品の拡大、免疫療法アプローチの台頭、診断における人工知能（AI）の利用強化、低侵襲手術技術の開発などがあります。

腫瘍学研究・医療への投資の拡大が、今後数年の腫瘍学研究・医療市場拡大の原動力になると予測されます。腫瘍学研究・医療への投資とは、政府、製薬会社、研究機関、非公開投資家が、がんの予防、診断、治療を進歩させるために行う財政的コミットメントを指します。このような投資の増加は、世界のがん罹患率の上昇、精密医療の進歩、革新的な治療法に対する需要の高まり、臨床検査の拡大、政府や民間の資金提供イニシアティブ、標的療法や免疫療法の開発によって促進されています。これらの投資は、早期診断の改善、標的療法や免疫療法などの治療選択肢の強化、より効果的な薬剤の臨床検査への資金提供、小児がん治療のインフラ強化、疾患の生物学的性質と進行の理解を深めるための革新的研究の促進などにより、傍神経節腫の進歩を支えています。例えば、2024年5月、高度分析を専門とするインドの情報技術企業IQVIAは、2023年の世界のがん医療への支出が2022年から250億米ドル増の2,230億米ドルに増加し、2028年には4,090億米ドルに達すると予測していると報告しました。その結果、がん研究・医療への投資の増加が傍神経節腫市場の成長を後押ししています。

傍神経節腫市場の主要企業は、経口低酸素誘導性因子-2α（HIF-2a）阻害剤などの先進治療の開発を優先し、患者に標的治療の選択肢を提供しています。経口HIF-2a阻害剤は、低酸素条件下での腫瘍増殖の重要な因子であるHIF-2a活性を阻害する標的治療であり、それによって傍神経節腫のような状態でのがんの進行を遅らせる。例えば、2025年1月、米国のバイオ医薬品会社であるMerck社は、ウェリレグ（ベルズチファン）の新薬追加申請が、米国の政府機関である米国食品医薬品局（FDA）から優先審査を受けたと発表しました。Weliregは、進行性、切除不能または転移性の褐色細胞腫と傍神経節腫（PPGL）の成人と小児患者（12歳以上）を対象としています。今回の追加新薬承認申請（sNDA）は、第2相臨床検査LITESPARK-015の客観的奏効率（ORR）と奏効期間（DOR）データにより裏付けられたものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の傍神経節腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の傍神経節腫市場：成長率分析
• 世界の傍神経節腫市場の実績：規模と成長、2019～2024年
• 世界の傍神経節腫市場の予測：規模と成長、2024～2029年、2034年
• 世界の傍神経節腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の傍神経節腫市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 交感神経性傍神経節腫
• 副交感神経傍神経節腫
• 頸動脈傍神経節腫
• 頸部傍神経節腫
• 頸静脈傍神経節腫
• 分泌性傍神経節腫
• 側頭葉傍神経節腫
• 世界の傍神経節腫市場：原因部位別、実績と予測、2019～2024年、2024～2029年、2034年
• 頭頸部
• 腹部
• 骨盤
• その他の原因部位
• 世界の傍神経節腫市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ペプチド受容体放射性核種療法
• 手術
• 化学療法
• 放射線治療
• その他の治療タイプ
• 世界の傍神経節腫市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• ドラッグストアと薬局
• オンライン薬局
• 世界の傍神経節腫市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• がん研究機関
• その他
• 世界の傍神経節腫市場、交感神経性傍神経節腫のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 副腎交感神経傍神経節腫
• 副腎外交感神経節腫
• 世界の傍神経節腫市場、副交感神経傍神経節腫のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 頭頸部副交感神経節腫
• 胸部副交感神経傍神経節腫
• 世界の傍神経節腫市場、頸動脈傍神経節腫のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 片側頸動脈傍神経節腫
• 両側頸動脈傍神経節腫
• 世界の傍神経節腫市場、頸部傍神経節腫のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 迷走神経節腫
• 舌下神経節腫
• 世界の傍神経節腫市場、頸静脈傍神経節腫のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• A型
• タイプB
• タイプC
• タイプD
• 世界の傍神経節腫市場、分泌性傍神経節腫のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• カテコールアミン分泌性傍神経節腫
• 非カテコールアミン分泌性傍神経節腫
• 世界の傍神経節腫市場、側頭葉傍神経節腫のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 鼓室傍神経節腫
• 乳様突起傍神経節腫

第7章 地域別・国別分析

• 世界の傍神経節腫市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の傍神経節腫市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 傍神経節腫市場：競合情勢
• 傍神経節腫市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Mount Sinai
  • Penn Medicine
  • Stanford Health Care

第31章 その他の大手企業と革新的企業

• St. Jude Children's Research Hospital
• UT Health San Antonio
• The University of Chicago Medical Center
• Fred Hutchinson Cancer Center
• Florida Cancer Specialists & Research Institute
• Invitae Corp.
• Clinigen Group plc
• Fulgent Genetics
• Dana-Farber Cancer Institute Inc.
• Oncology Hematology Care Inc.
• Enterome
• National Institutes of Health Clinical Center
• Progenics Pharmaceuticals Inc.
• Pheo Para Alliance
• Saint John's Cancer Institute

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 傍神経節腫市場、2029年：新たな機会を提供する国
• 傍神経節腫市場、2029年：新たな機会を提供するセグメント
• 傍神経節腫市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Paraganglioma is a rare neuroendocrine tumor that arises from paraganglia, clusters of cells associated with the autonomic nervous system. These tumors are typically found in the head, neck, chest, or abdomen and may produce excess hormones, posing a risk of malignancy. Early diagnosis is crucial for effective management and preventing complications.

The main types of paraganglioma include sympathetic, parasympathetic, carotid, cervical, jugular, secretory, and temporal paragangliomas. Sympathetic paragangliomas, which develop in the sympathetic nervous system, often produce catecholamines. These tumors originate from various locations, such as the head and neck, abdomen, pelvis, and other areas. Treatment options include peptide receptor radionuclide therapy, surgery, chemotherapy, radiation therapy, and other approaches. These treatments are distributed through hospital pharmacies, drug stores, retail pharmacies, and online pharmacies, catering to end-users such as hospitals, specialty clinics, and cancer research institutes.

The paraganglioma market research report is one of a series of new reports from The Business Research Company that provides paraganglioma market statistics, including the paraganglioma industry global market size, regional shares, competitors with the paraganglioma market share, detailed paraganglioma market segments, market trends, and opportunities, and any further data you may need to thrive in the paraganglioma industry. This paraganglioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The paraganglioma market size has grown strongly in recent years. It will grow from $2.89 billion in 2024 to $3.03 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to advancements in diagnostic imaging, increased awareness and screening programs, regulatory approvals for targeted therapies, the expansion of specialized treatment centers, and progress in genetic testing.

The paraganglioma market size is expected to see strong growth in the next few years. It will grow to $3.64 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to emerging targeted therapies and immunotherapies, the expansion of radiopharmaceuticals, the rising prevalence of genetic diseases, increasing investments in rare disease research, and improved healthcare access in emerging markets. Major trends expected during this period include advancements in targeted therapies, the expansion of radiopharmaceuticals, the rise of immunotherapy approaches, enhanced use of artificial intelligence (AI) in diagnostics, and the development of minimally invasive surgical techniques.

The growing investments in oncology research and medicine are expected to drive the expansion of the paraganglioma market in the coming years. Investments in oncology research and medicine refer to financial commitments made by governments, pharmaceutical companies, research institutions, and private investors to advance cancer prevention, diagnosis, and treatment. The increase in such investments is fueled by the rising global cancer burden, advancements in precision medicine, growing demand for innovative therapies, expansion of clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments. These investments support advancements in paraganglioma by improving early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, strengthening pediatric cancer care infrastructure, and fostering innovative research to better understand the disease's biology and progression. For instance, in May 2024, IQVIA, an India-based information technology company specializing in advanced analytics, reported that global spending on cancer medicine increased to $223 billion in 2023, a $25 billion rise from 2022, and is projected to reach $409 billion by 2028. As a result, the increasing investments in oncology research and medicine are fueling the growth of the paraganglioma market.

Leading companies in the paraganglioma market are prioritizing the development of advanced therapies such as oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitors to provide targeted treatment options for patients. An oral HIF-2a inhibitor is a targeted therapy that inhibits HIF-2a activity, a key factor in tumor growth under low-oxygen conditions, thereby slowing cancer progression in conditions such as paraganglioma. For example, in January 2025, Merck, a US-based biopharmaceutical company, announced that its supplemental new drug application for Welireg (belzutifan) received priority review from the U.S. Food and Drug Administration (FDA), a US-based government agency. Welireg is intended for adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). The supplemental new drug application (sNDA) is supported by objective response rate (ORR) and duration of response (DOR) data from the Phase 2 LITESPARK-015 trial.

In January 2022, Exact Sciences Corp., a US-based molecular diagnostics company, acquired PreventionGenetics for an undisclosed amount. This acquisition was aimed at expanding Exact Sciences' hereditary cancer testing capabilities, increasing access to early detection and personalized treatment options. PreventionGenetics, a US-based clinical genetic testing laboratory, specializes in genetic testing for hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome.

Major players in the paraganglioma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mount Sinai, Penn Medicine, Stanford Health Care, St. Jude Children's Research Hospital, UT Health San Antonio, The University of Chicago Medical Center, Fred Hutchinson Cancer Center, Florida Cancer Specialists & Research Institute, Invitae Corp., Clinigen Group plc, Fulgent Genetics, Dana-Farber Cancer Institute Inc., Oncology Hematology Care Inc., Enterome, National Institutes of Health Clinical Center, Progenics Pharmaceuticals Inc., Pheo Para Alliance, Saint John's Cancer Institute.

North America was the largest region in the paraganglioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in paraganglioma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the paraganglioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The paraganglioma market consists of revenues earned by entities by providing services such as diagnosis & screening services, post-treatment and support services, and clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The paraganglioma market also includes sales of imaging kits, alpha-adrenergic blockers, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Paraganglioma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on paraganglioma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for paraganglioma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The paraganglioma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Sympathetic Paragangliomas; Parasympathetic Paragangliomas; Caroid Paragangliomas; Cervical Paragangliomas; Jugular Paragangliomas; Secretory Paragangliomas; Temporal Paragangliomas
• 2) By Origin: Head And Neck; Abdomen; Pelvis; Other Origins
• 3) By Treatment Type: Peptide Receptor Radionuclide Therapy; Surgery; Chemotherapy; Radiation Therapy; Other Treatment Types
• 4) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Pharmacies
• 5) By End-User: Hospitals; Specialty Clinics; Cancer Research Institutes; Other End-Users
• Subsegments:
• 1) By Sympathetic Paragangliomas: Adrenal Sympathetic Paragangliomas; Extra-Adrenal Sympathetic Paragangliomas
• 2) By Parasympathetic Paragangliomas: Head And Neck Parasympathetic Paragangliomas; Thoracic Parasympathetic Paragangliomas
• 3) By Carotid Paragangliomas: Unilateral Carotid Paragangliomas; Bilateral Carotid Paragangliomas
• 4) By Cervical Paragangliomas: Vagal Paragangliomas; Hypoglossal Paragangliomas
• 5) By Jugular Paragangliomas: Type A; Type B; Type C; Type D
• 6) By Secretory Paragangliomas: Catecholamine-Secreting Paragangliomas; Non-Catecholamine-Secreting Paragangliomas
• 7) By Temporal Paragangliomas: Tympanic Paragangliomas; Mastoid Paragangliomas
• Companies Mentioned:F. Hoffmann-La Roche Ltd.; Merck & Co. Inc. ; Mount Sinai; Penn Medicine; Stanford Health Care
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Paraganglioma Market Characteristics

3. Paraganglioma Market Trends And Strategies

4. Paraganglioma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Paraganglioma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Paraganglioma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Paraganglioma Market Growth Rate Analysis
• 5.4. Global Paraganglioma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Paraganglioma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Paraganglioma Total Addressable Market (TAM)

6. Paraganglioma Market Segmentation

• 6.1. Global Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sympathetic Paragangliomas
• Parasympathetic Paragangliomas
• Caroid Paragangliomas
• Cervical Paragangliomas
• Jugular Paragangliomas
• Secretory Paragangliomas
• Temporal Paragangliomas
• 6.2. Global Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Head And Neck
• Abdomen
• Pelvis
• Other Origins
• 6.3. Global Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptide Receptor Radionuclide Therapy
• Surgery
• Chemotherapy
• Radiation Therapy
• Other Treatment Types
• 6.4. Global Paraganglioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Stores And Retail Pharmacies
• Online Pharmacies
• 6.5. Global Paraganglioma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Cancer Research Institutes
• Other End-Users
• 6.6. Global Paraganglioma Market, Sub-Segmentation Of Sympathetic Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adrenal Sympathetic Paragangliomas
• Extra-Adrenal Sympathetic Paragangliomas
• 6.7. Global Paraganglioma Market, Sub-Segmentation Of Parasympathetic Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Head And Neck Parasympathetic Paragangliomas
• Thoracic Parasympathetic Paragangliomas
• 6.8. Global Paraganglioma Market, Sub-Segmentation Of Carotid Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Unilateral Carotid Paragangliomas
• Bilateral Carotid Paragangliomas
• 6.9. Global Paraganglioma Market, Sub-Segmentation Of Cervical Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vagal Paragangliomas
• Hypoglossal Paragangliomas
• 6.10. Global Paraganglioma Market, Sub-Segmentation Of Jugular Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type A
• Type B
• Type C
• Type D
• 6.11. Global Paraganglioma Market, Sub-Segmentation Of Secretory Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Catecholamine-Secreting Paragangliomas
• Non-Catecholamine-Secreting Paragangliomas
• 6.12. Global Paraganglioma Market, Sub-Segmentation Of Temporal Paragangliomas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tympanic Paragangliomas
• Mastoid Paragangliomas

7. Paraganglioma Market Regional And Country Analysis

• 7.1. Global Paraganglioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Paraganglioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Paraganglioma Market

• 8.1. Asia-Pacific Paraganglioma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Paraganglioma Market

• 9.1. China Paraganglioma Market Overview
• 9.2. China Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Paraganglioma Market

• 10.1. India Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Paraganglioma Market

• 11.1. Japan Paraganglioma Market Overview
• 11.2. Japan Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Paraganglioma Market

• 12.1. Australia Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Paraganglioma Market

• 13.1. Indonesia Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Paraganglioma Market

• 14.1. South Korea Paraganglioma Market Overview
• 14.2. South Korea Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Paraganglioma Market

• 15.1. Western Europe Paraganglioma Market Overview
• 15.2. Western Europe Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Paraganglioma Market

• 16.1. UK Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Paraganglioma Market

• 17.1. Germany Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Paraganglioma Market

• 18.1. France Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Paraganglioma Market

• 19.1. Italy Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Paraganglioma Market

• 20.1. Spain Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Paraganglioma Market

• 21.1. Eastern Europe Paraganglioma Market Overview
• 21.2. Eastern Europe Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Paraganglioma Market

• 22.1. Russia Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Paraganglioma Market

• 23.1. North America Paraganglioma Market Overview
• 23.2. North America Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Paraganglioma Market

• 24.1. USA Paraganglioma Market Overview
• 24.2. USA Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Paraganglioma Market

• 25.1. Canada Paraganglioma Market Overview
• 25.2. Canada Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Paraganglioma Market

• 26.1. South America Paraganglioma Market Overview
• 26.2. South America Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Paraganglioma Market

• 27.1. Brazil Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Paraganglioma Market

• 28.1. Middle East Paraganglioma Market Overview
• 28.2. Middle East Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Paraganglioma Market

• 29.1. Africa Paraganglioma Market Overview
• 29.2. Africa Paraganglioma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Paraganglioma Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Paraganglioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Paraganglioma Market Competitive Landscape And Company Profiles

• 30.1. Paraganglioma Market Competitive Landscape
• 30.2. Paraganglioma Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mount Sinai Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Penn Medicine Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Stanford Health Care Overview, Products and Services, Strategy and Financial Analysis

31. Paraganglioma Market Other Major And Innovative Companies

• 31.1. St. Jude Children's Research Hospital
• 31.2. UT Health San Antonio
• 31.3. The University of Chicago Medical Center
• 31.4. Fred Hutchinson Cancer Center
• 31.5. Florida Cancer Specialists & Research Institute
• 31.6. Invitae Corp.
• 31.7. Clinigen Group plc
• 31.8. Fulgent Genetics
• 31.9. Dana-Farber Cancer Institute Inc.
• 31.10. Oncology Hematology Care Inc.
• 31.11. Enterome
• 31.12. National Institutes of Health Clinical Center
• 31.13. Progenics Pharmaceuticals Inc.
• 31.14. Pheo Para Alliance
• 31.15. Saint John's Cancer Institute

32. Global Paraganglioma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Paraganglioma Market

34. Recent Developments In The Paraganglioma Market

35. Paraganglioma Market High Potential Countries, Segments and Strategies

• 35.1 Paraganglioma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Paraganglioma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Paraganglioma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer